

UPDATE REGARDING THE DIVESTMENT OF FRISQ HOLDING AB'S SUBSIDIARIES

At the Extraordinary General Meeting on February 22nd 2022, the shareholders present voted in favor of a sale of FRISQ Holding's subsidiaries to Tempest SPV Ltd, subject to the conditions that the purchase price was not changed (SEK 106.4 million), the share purchase agreement took place on market terms and that signing would take place no later than February 28th 2022, 23.59 CET. Due to a serious illness, the buyer has requested a deferral of submitting a signed and binding share purchase agreement. The board has therefore decided to give the buyer a deferral to submit the necessary documentation.

The Board will convene a new Extraordinary General Meeting to approve the divestment, provided that there is a signed share purchase agreement.

For further information:

George Thaw, CEO, FRISQ
investor@frisq.se

About FRISQ:

FRISQ is a healthtech company built on the conviction that the quality of the care you get should not be dependent on your ability to navigate a complex system and constantly evolving treatments. The software solution [FRISQ Care](#) enables the creation of personalized, digital care plans that facilitate collaboration and secure information sharing between care teams, doctors and patients through the same platform.

Since 2016, FRISQ has been listed on Nasdaq First North Stockholm under the symbol "FRISQ". FNCA Sweden AB is FRISQ's Certified Adviser and can be reached via the following contact information: +46 8 528 00 399, info@fnca.se

The publication is a translation of the original Swedish text. In the event of inconsistency or discrepancy between the Swedish version and this publication, the Swedish language version shall prevail.

For more information, please visit: www.frisqholding.se

Attachments

[Update regarding the divestment of FRISQ Holding AB's subsidiaries](#)